Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review

Yahoo FinanceMay 11 03:36

Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review

TipRanksMay 10 13:26

RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)

TipRanksMay 9 18:49

Design Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 42.86 percent increase over losses of

BenzingaMay 9 05:21

Design Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 04:55 · Announcements

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients

GlobeNewswireMay 9 04:05